Clarity Pharmaceuticals reports two additional complete responses in SECuRE trial 8 GBq 67Cu-SAR-bisPSMA cohort

Reuters2026/08/05 13:04

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Clarity Pharmaceuticals released a SECuRE trial update on Aug. 5, 2026, covering an interim data cut-off of July 20, 2026.
The ongoing study of 67Cu-SAR-bisPSMA at the 8 GBq dose showed meaningful tumor responses in heavily pretreated metastatic prostate cancer patients.
Radiographic reviews indicated many patients avoided disease worsening, with multiple cases reaching complete response or undetectable disease.
Two additional complete responses were identified in the cohort expansion, lifting the program total to seven complete response or undetectable disease cases.
Safety was described as generally favorable, with mostly mild-to-moderate side effects and no high-grade related events reported.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clarity Pharmaceuticals Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608050902PR_NEWS_USPR_____CN19574) on August 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Clarity Pharmaceuticals reports two additional complete responses in SECuRE trial 8 GBq 67Cu-SAR-bisPSMA cohort

You may also like

Crypto prices